Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: Role of Akt and nuclear factor-κB

Cancer Letters

Volumn 301, Issue 1, 2011, Pages 75-84

  Ma, Yong ^a   Wang, Jizhou ^a   Liu, Lianxin ^a   Zhu, Huaqiang ^a   Chen, Xiaoning ^b   Pan, Shangha ^a   Sun, Xueying ^a,c   Jiang, Hongchi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Akt; Apoptosis; Genistein; Hepatocellular carcinoma; NF B

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN D1; CYCLOOXYGENASE 2; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; DRUG SYNERGISM; GENISTEIN; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; NF-KAPPA B; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 78650582952     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.022     Document Type: Article

References (39)

1. Lau W.Y., Lai E.C. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann. Surg. 2009, 249:20-25.
2. Roberts L.R. Sorafenib in liver cancer - just the beginning. New Engl. J. Med. 2008, 359:420-422.
3. Newell P., Villanueva A., Llovet J.M. Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J. Hepatol. 2008, 49:1-5.
4. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 2001, 6:11-16.
5. Luo L., Qiao H., Meng F., Dong X., Zhou B., Jiang H., Kanwar J.R., Krissansen G.W., Sun X. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int. J. Cancer 2006, 118:1823-1830.
6. Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G.W., Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006, 97:675-681.
7. Oketani M., Kohara K., Tuvdendorj D., Ishitsuka K., Komorizono Y., Ishibashi K., Arima T. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett. 2002, 183:147-153.
8. Kito M., Matsumoto K., Wada N., Sera K., Futatsugawa S., Naoe T., Nozawa Y., Akao Y. Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci. 2003, 94:1010-1014.
9. Shen Z.X., Shi Z.Z., Fang J., Gu B.W., Li J.M., Zhu Y.M., Shi J.Y., Zheng P.Z., Yan H., Liu Y.F., Chen Y., Shen Y., Wu W., Tang W., Waxman S., De ThéH., Wang Z.Y., Chen S.J., Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Nat. Acad. Sci. USA 2004, 101:5328-5335.
10. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., Wu W., Zhang F.Q., Chen Y., Zhou L., Li J.M., Zeng X.Y., Yang R.R., Yuan M.M., Ren M.Y., Gu F.Y., Cao Q., Gu B.W., Su X.Y., Chen G.Q., Xiong S.M., Zhang T.D., Waxman S., Wang Z.Y., Chen Z., Hu J., Shen Z.X., Chen S.J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
11. Lin C.C., Hsu C., Hsu C.H., Hsu W.L., Cheng A.L., Yang C.H. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest. New Drugs 2007, 25:77-84.
12. Omar H.A., Sargeant A.M., Weng J.R., Wang D., Kulp S.K., Patel T., Chen C.S. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol. Pharmacol. 2009, 76:957-968.
13. Hu T.H., Huang C.C., Lin P.R., Chang H.W., Ger L.P., Lin Y.W., Changchien C.S., Lee C.M., Tai M.H. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003, 97:1929-1940.
14. Kim H.R., Lee S.H., Jung G. The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of TBK1. FEBS Lett. 2010, 584:525-530.
15. Feng Y.X., Zhao J.S., Li J.J., Wang T., Cheng S.Q., Yuan Y., Wang F., Wang X.F., Xie D. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway 120:. Hepatology 2010, 51:535-544.
16. Wu J.M., Sheng H., Saxena R., Skill N.J., Bhat-Nakshatri P., Yu M., Nakshatri H., Maluccio M.A. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009, 278:145-155.
17. Banerjee S., Li Y., Wang Z., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008, 269:226-242.
18. Mai Z., Blackburn G.L., Zhou J.R. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis 2007, 28:1217-1223.
19. Burich R.A., Holland W.S., Vinall R.L., Tepper C., White R.W., Mack P.C. Genistein combined polysaccharide enhances activity of docetaxel bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int. 2008, 102:1458-1466.
20. El-Rayes B.F., Ali S., Ali I.F., Philip P.A., Abbruzzese J., Sarkar F.H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006, 66:10553-10559.
21. Gu Y., Zhu C.F., Iwamoto H., Chen J.S. Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J. Gastroenterol. 2005, 11:6512-6517.
22. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappa B by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65:6934-6942.
23. Sturlan S., Baumgartner M., Roth E., Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003, 101:4990-4997.
24. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991, 19:2499.
25. Liu F., Wang P., Jiang X., Tan G., Qiao H., Jiang H., Krissansen G.W., Sun X. Antisense hypoxia- inducible factor 1 α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci. 2008, 99:2055-2061.
26. Zhou J.R., Mukherjee P., Gugger E.T., Tanaka T., Blackburn G.L., Clinton S.K. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res. 1998, 58:5231-5238.
27. Shimamura H., Terada Y., Okado T., Tanaka H., Inoshita S., Sasaki S. The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad. J. Am. Soc. Nephrol. 2003, 14:1427-1434.
28. Vichalkovski A., Gresko E., Hess D., Restuccia D.F., Hemmings B.A. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 2010, 29:3554-3565.
29. Kim S.H., Kim S.H., Kim Y.B., Jeon Y.T., Lee S.C., Song Y.S. Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann. NY Acad. Sci. 2009, 1171:495-500.
30. Yan G.R., Xiao C.L., He G.W., Yin X.F., Chen N.P., Cao Y., He Q.Y. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics 2010, 10:976-986.
31. Gadgeel S.M., Ali S., Philip P.A., Wozniak A., Sarkar F.H. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009, 115:2165-2176.
32. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
33. Lau C.K., Yang Z.F., Ho D.W., Ng M.N., Yeoh G.C., Poon R.T., Fan S.T. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin. Cancer Res. 2009, 15:3462-3471.
34. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103:307-312.
35. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
36. Chen K.F., Yeh P.Y., Yeh K.H., Lu Y.S., Huang S.Y., Cheng A.L. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2008, 68:6698-6707.
37. Aggarwal B.B. Nuclear factor-κB: the enemy within. Cancer Cell. 2004, 6:203-208.
38. Reddy S.A., Huang J.H., Liao W.S. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation. J. Immunol. 2000, 164:1355-1363.
39. Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J., Baldwin A.S., Mayo M.W. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell Biol. 2000, 20:1626-1638.